LOXL2 Inhibitors

LOXL2 inhibitors for multiple indications

Pharmaxis has developed two first-in-class, mechanism-based small molecules that inhibit Lysyl Oxidase Like 2 (LOXL-2) for the treatment of fibrotic diseases including NASH, liver, IPF, heart and kidney fibrosis.

The two lead compounds, each with differentiated PK / PD profile have demonstrated efficacy in pre clinical models of fibrosis and have successfully completed phase 1 clinical trials.

In addition to studying the safety and pharmacokinetic profile, the clinical trials also investigated the degree to which the drug can inhibit the target enzyme LOXL2 which is implicated in several different fibrotic diseases. Importantly, Pharmaxis has been able to demonstrate a large and highly significant inhibition of this enzyme in blood serum for a full 24 hours from a single dose and that daily dosing over a 14-day period now meets our targeted  effect of greater than 80% inhibition.

The LOXL2 program has been conducted in collaboration with UK biotechnology company Synairgen plc (LSE: SNG).

Access Pharmaxis Publications and Posters on LOXL2 inhibitors

Skip to

Fibrosis

Phase I
Description Phase 1 clinical trial - first compound
Sites Two phase 1 units in Australia
Subjects Single Ascending Dose stage: 48; Multiple Ascending Dose stage: 24
Status Complete
More Information
Media Releases
Phase I
Description Phase 1 clinical trial - second compound
Sites Two phase 1 units in Australia
Subjects Single Ascending Dose stage: 48; Multiple Ascending Dose stage: 24
Status Complete
More Information
Media Releases